Research & Development News Channel

The cellular response that protects pigs from COVID-19

Iowa State University scientists may have uncovered an important clue that sheds light on why pigs don’t get sick when exposed to the coronavirus.

Studies since the start of the pandemic have noted that pigs can be infected by the virus if exposed to high doses, but the infection is self-limited and pigs don’t show clinical signs of disease nor do they transmit the virus to other animals.

An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections

More than 1.2 million people - and potentially millions more - died in 2019 as a direct result of antibiotic-resistant bacterial infections, according to the most comprehensive estimate to date of the global impact of antimicrobial resistance (AMR).

The analysis of 204 countries and territories, published in The Lancet, reveals that AMR is now a leading cause of death worldwide, higher than HIV/AIDS or malaria.

Placebo effect accounts for more than two-thirds of COVID-19 vaccine adverse events

The placebo effect is the well-known phenomenon of a person's physical or mental health improving after taking a treatment with no pharmacological therapeutic benefit - a sugar pill, or a syringe full of saline, for example. While the exact biological, psychological and genetic underpinnings of the placebo effect are not well understood, some theories point to expectations as the primary cause and others argue that non-conscious factors embedded in the patient-physician relationship automatically turn down the volume of symptoms.

WHO recommends two new drugs to treat patients with COVID-19

The drug baricitinib (a type of drug known as a Janus kinase (JAK) inhibitor, also used to treat rheumatoid arthritis) is strongly recommended for patients with severe or critical COVID-19 in combination with corticosteroids, says a WHO Guideline Development Group of international experts in The BMJ.

Research team finds new dual benefit mode of action for a drug candidate to fight COVID-19

A research team led by Prof. Stephan Ludwig, a virologist at the Institute of Virology at the University of Münster, has found a new dual attack mode of action while working on the development of a drug candidate against SARS-CoV-2 infections. This could constitute the basis for a broadly effective drug to fight COVID 19.

COVID-19 - Omicron: resistant to most monoclonal antibodies but neutralized by a booster dose

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant within a few weeks or months. Initial epidemiological studies show that the Omicron variant is more transmissible than the currently dominant virus (the Delta variant). It is capable of spreading to individuals who have received two vaccine doses and to previously infected individuals.

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild symptoms or no symptoms at all, according to Cedars-Sinai investigators. The findings are published in the Journal of Translational Medicine.

Research & Development News

The cellular response that protects pigs from COVID-19

An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections

Placebo effect accounts for more than two-thirds of COVID-19 vaccine adverse events

WHO recommends two new drugs to treat patients with COVID-19

Research team finds new dual benefit mode of action for a drug candidate to fight COVID-19

COVID-19 - Omicron: resistant to most monoclonal antibodies but neutralized by a booster dose

COVID-19 can trigger self-attacking antibodies

More Pharma News ...

Business & Industry

Research & Development

Conferences & Events

Regulatory Affairs